Close X

The myESMO community is an international network of over 6'000 oncology professionals, sharing best practices and the latest know-how in cancer treatment and care

Join myESMO
to access our members only benefits

Click to discover ESMO

Already have an
ESMO Account?

 
Username: Password:
Remember me!
Forgot your Password?
Close X

You are trying to access a members only resource.
Please log-in.

 
Username: Password:
Remember me!

Forgot your Password?

join us

Not a Member yet?

Get involved, stay connected:
Join myESMO community today

Oncology News

10.03.10 Natural history and management of everolimus-induced oral ulcers

Everolimus-induced oral ulcers are very frequent and sometimes harmful complication



04.03.10 Actively targeting mTOR

Selective inhibitors of TORC1 and TORC2 might be superior to those that also inhibit PI3K and to rapamycin, and might be particularly effective when used with regimens that include dasatinib for treating Ph+ B-ALL



03.03.10 Kinase inhibitors: A winning combination against BCR–ABL

A selective allosteric inhibitor of BCR–ABL, GNF-5, cooperates with ATP competitive inhibitors to inhibit both wild-type and mutant forms of the kinase



Displaying results 1 to 5 out of 275

1

2

3

4

5

6

7

Next >